Indivior To Appeal US Suboxone Setback, Flags Follow-On Drug RBP-6000
Shares in Indivior slid nearly 40% on news of a US court ruling which raises chances its key opioid addiction treatment may face generic competition sooner than expected.
Shares in Indivior slid nearly 40% on news of a US court ruling which raises chances its key opioid addiction treatment may face generic competition sooner than expected.